BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gleichenhagen J, Arndt C, Casjens S, Meinig C, Gerullis H, Raiko I, Brüning T, Ecke T, Johnen G. Evaluation of a New Survivin ELISA and UBC® Rapid for the Detection of Bladder Cancer in Urine. Int J Mol Sci 2018;19:E226. [PMID: 29324722 DOI: 10.3390/ijms19010226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ecke TH, Kiani A, Schlomm T, Friedersdorff F, Rabien A, Jung K, Kilic E, Boström P, Tervahartiala M, Taimen P, Gleichenhagen J, Johnen G, Brüning T, Koch S, Roggisch J, Wirtz RM. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy. Int J Mol Sci 2020;21:E7420. [PMID: 33050010 DOI: 10.3390/ijms21197420] [Reference Citation Analysis]
2 Lokeshwar SD, Lopez M, Sarcan S, Aguilar K, Morera DS, Shaheen DM, Lokeshwar BL, Lokeshwar VB. Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. Cancers (Basel) 2022;14:2578. [PMID: 35681556 DOI: 10.3390/cancers14112578] [Reference Citation Analysis]
3 Lu P, Cui J, Chen K, Lu Q, Zhang J, Tao J, Han Z, Zhang W, Song R, Gu M. Diagnostic accuracy of the UBC® Rapid Test for bladder cancer: A meta-analysis. Oncol Lett 2018;16:3770-8. [PMID: 30127987 DOI: 10.3892/ol.2018.9089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Barani M, Hosseinikhah SM, Rahdar A, Farhoudi L, Arshad R, Cucchiarini M, Pandey S. Nanotechnology in Bladder Cancer: Diagnosis and Treatment. Cancers (Basel) 2021;13:2214. [PMID: 34063088 DOI: 10.3390/cancers13092214] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Feldman AS, Lokeshwar V, Lin DW. A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers. Urol Oncol 2021:S1078-1439(21)00269-6. [PMID: 34315659 DOI: 10.1016/j.urolonc.2021.06.010] [Reference Citation Analysis]
6 Sanli O, Lotan Y. Current approaches for identifying high-risk non-muscle invasive bladder cancer. Expert Review of Anticancer Therapy 2018;18:223-35. [DOI: 10.1080/14737140.2018.1432358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Agreda Castañeda F, Raventós Busquets CX, Morote Robles J. Assessing the Clinical Benefit of UBC Rapid in the Surveillance and Initial Diagnosis of Bladder Cancer. Clinical Genitourinary Cancer 2020;18:230-5. [DOI: 10.1016/j.clgc.2019.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Stobiecka M, Ratajczak K, Jakiela S. Toward early cancer detection: Focus on biosensing systems and biosensors for an anti-apoptotic protein survivin and survivin mRNA. Biosens Bioelectron 2019;137:58-71. [PMID: 31078841 DOI: 10.1016/j.bios.2019.04.060] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
9 Pezzuto F, Scarano A, Marini C, Rossi G, Stocchi R, Di Cerbo A, Di Cerbo A. Assessing the Reliability of Commercially Available Point of Care in Various Clinical Fields. TOPHJ 2019;12:342-68. [DOI: 10.2174/1874944501912010342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
10 Ahn J, Kang C, Kim E, Kim A, Kim A. Proteomics for Early Detection of Non-Muscle-Invasive Bladder Cancer: Clinically Useful Urine Protein Biomarkers. Life 2022;12:395. [DOI: 10.3390/life12030395] [Reference Citation Analysis]
11 Benderska-Söder N, Hovanec J, Pesch B, Goebell PJ, Roghmann F, Noldus J, Rabinovich J, Wichert K, Gleichenhagen J, Käfferlein HU, Köhler CU, Johnen G, Kernig K, Hakenberg O, Jahn D, Todenhöfer T, Stenzl A, Gleissner J, Gerwert K, El-Mashtoly S, Behrens T, Brüning T, Schmitz-Dräger BJ. Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial. Urol Oncol 2020;38:886-95. [PMID: 32199755 DOI: 10.1016/j.urolonc.2020.01.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
12 Ecke TH, Weiß S, Stephan C, Hallmann S, Arndt C, Barski D, Otto T, Gerullis H. UBC® Rapid Test-A Urinary Point-of-Care (POC) Assay for Diagnosis of Bladder Cancer with a focus on Non-Muscle Invasive High-Grade Tumors: Results of a Multicenter-Study. Int J Mol Sci 2018;19:E3841. [PMID: 30513851 DOI: 10.3390/ijms19123841] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 Shlyapnikov YM, Malakhova EA, Vinarov AZ, Zamyatnin AA Jr, Shlyapnikova EA. Can new immunoassay techniques improve bladder cancer diagnostics With protein biomarkers? Front Mol Biosci 2020;7:620687. [PMID: 33659273 DOI: 10.3389/fmolb.2020.620687] [Reference Citation Analysis]
14 Crocetto F, Barone B, Ferro M, Busetto GM, La Civita E, Buonerba C, Di Lorenzo G, Terracciano D, Schalken JA. Liquid biopsy in bladder cancer: State of the art and future perspectives. Crit Rev Oncol Hematol 2022;170:103577. [PMID: 34999017 DOI: 10.1016/j.critrevonc.2022.103577] [Reference Citation Analysis]
15 Sugeeta SS, Sharma A, Ng K, Nayak A, Vasdev N. Biomarkers in Bladder Cancer Surveillance. Front Surg 2021;8:735868. [PMID: 34651010 DOI: 10.3389/fsurg.2021.735868] [Reference Citation Analysis]
16 Humayun-Zakaria N, Ward DG, Arnold R, Bryan RT. Trends in urine biomarker discovery for urothelial bladder cancer: DNA, RNA, or protein? Transl Androl Urol 2021;10:2787-808. [PMID: 34295762 DOI: 10.21037/tau-20-1327] [Reference Citation Analysis]